Sterols Panel

Two people can have the same LDL cholesterol number and need completely different treatments. One person's cholesterol is high because their intestines absorb too much of it from food. The other person's liver is manufacturing too much on its own. A standard lipid panel cannot tell you which one you are. This panel can.

The Sterols Panel measures plant sterols and cholesterol precursors circulating in your blood. Together, these markers sort you into one of two metabolic profiles, a high absorber or a high synthesizer, and that distinction changes which medications, supplements, and dietary strategies will actually lower your LDL.

Why Absorption and Synthesis Are a Seesaw

Your body keeps cholesterol in a rough balance. When your intestines absorb more cholesterol from food and bile, your liver dials back its own production. When absorption drops, the liver ramps up manufacturing. These two pathways are inversely linked, like opposite ends of a seesaw.

The panel captures both sides of this seesaw with two categories of markers. Plant sterols (campesterol and beta-sitosterol) travel the same intestinal absorption pathway as cholesterol. Because your body cannot make them, their blood levels directly reflect how efficiently your gut absorbs sterols from your diet. Higher levels mean you are a stronger absorber.

On the other side, lathosterol and desmosterol are molecules your liver produces as intermediate steps while building cholesterol. When synthesis is running high, more of these precursors spill into the bloodstream. Elevated levels mark you as a high synthesizer.

What This Panel Reveals

The panel answers three questions that a standard lipid panel leaves entirely unanswered.

• Is your cholesterol driven by absorption, synthesis, or a mix of both?
• Which class of cholesterol-lowering therapy is most likely to work for you?
• Do you carry a pattern of sterol absorption associated with higher cardiovascular risk?

In the PROCAM cohort (Prospective Cardiovascular Munster study), men with elevated plasma sitosterol levels had a significantly increased risk of coronary events, independent of standard risk factors. A separate analysis from the LURIC (Ludwigshafen Risk and Cardiovascular Health) study found that higher ratios of campesterol and sitosterol to cholesterol were associated with increased risk of death from cardiovascular and other causes.

These findings suggest that the absorption pattern itself may carry cardiovascular risk beyond what LDL alone predicts. This is one reason the panel matters even if your standard cholesterol numbers look acceptable.

Guiding Treatment: Statins, Ezetimibe, or Both

Statins work by blocking the liver enzyme responsible for cholesterol synthesis. They are most effective in people whose cholesterol is primarily driven by overproduction. A sub-analysis of patients in the Scandinavian Simvastatin Survival Study (4S) showed that patients with higher baseline synthesis markers had greater LDL reductions on simvastatin.

Ezetimibe works differently. It blocks cholesterol absorption in the intestine. Research has shown that patients' baseline absorption and synthesis profiles predict their response to different lipid-lowering therapies. Because ezetimibe specifically targets the absorption pathway, patients identified as high absorbers by sterol testing are the best candidates for this drug.

Without sterol testing, medication choice is essentially a guess followed by retesting. With it, you and your physician can start with the intervention most likely to move your numbers.

How to Read Your Results Together

The raw values of each sterol tell part of the story, but the normalized ratios (each sterol divided by total cholesterol) and the Cholesterol Balance Score are where interpretation begins. Normalization removes the effect of your total cholesterol level and isolates the metabolic signal.

The Cholesterol Balance Score simplifies this interpretation into a single number. It reflects the ratio between synthesis and absorption markers, giving you a quick read on which side of the seesaw you sit. A score tilted toward absorption means your gut is the primary driver. A score tilted toward synthesis points to your liver.

When Results Can Be Misleading

Several factors can temporarily shift your sterol levels. Statin therapy itself changes the balance: by suppressing synthesis, statins lower lathosterol and desmosterol while compensatorily increasing absorption markers. If you are already on a statin, your results will reflect the drug's effect, not your untreated baseline. Ideally, a first panel is drawn before starting lipid-lowering therapy, though results on therapy still have value for guiding combination approaches.

Diet matters too. A sudden increase in plant sterol intake (through fortified foods, margarine, or supplements) can raise campesterol and sitosterol levels without reflecting a true change in your absorption efficiency. Consistency in your usual diet for at least two to three weeks before testing gives the most reliable snapshot.

Liver disease and cholestasis (impaired bile flow) can raise plant sterol levels because the liver's ability to excrete absorbed sterols into bile is compromised. Markedly elevated plant sterols in someone with known liver problems should be interpreted cautiously.

Sitosterolemia: A Rare but Serious Connection

In rare cases, very high plant sterol levels point to sitosterolemia, a genetic condition caused by mutations in the ABCG5 or ABCG8 sterol transporter genes. People with this condition absorb far too many plant sterols and cannot excrete them efficiently, leading to levels many times higher than normal. They develop premature atherosclerosis (a buildup of fatty deposits in artery walls) and cholesterol deposits in tendons, sometimes with only modestly elevated total cholesterol on a standard panel.

People who carry just one copy of these gene mutations are far more common than those with full sitosterolemia and may show moderately elevated plant sterols with potentially increased cardiovascular risk, though research on this group is still limited. The Sterols Panel can flag this pattern, prompting genetic testing and targeted treatment with ezetimibe and dietary plant sterol restriction.

Tracking Over Time

A single sterol measurement establishes your metabolic profile. Serial testing, roughly every 6 to 12 months, shows whether your interventions are working on the right pathway. If you start ezetimibe and your absorption markers drop on the next panel, the drug is hitting its target. If they do not budge, you may need a different approach.

Sterol markers also shift with weight changes, dietary patterns, and aging. Tracking them alongside your standard lipid panel gives a much richer picture of what is actually driving your cholesterol trajectory than LDL alone ever could.

What to Do with Your Results

If your results clearly identify you as a high absorber or high synthesizer, bring the panel to your physician or cardiologist to discuss targeted therapy. For high absorbers, ezetimibe is the most evidence-backed pharmaceutical option. Dietary strategies include reducing cholesterol-rich foods and limiting supplemental plant sterols if your levels are already elevated.

For high synthesizers, statin therapy remains the first-line treatment with the strongest outcome data. If your absorption markers are also creeping up, adding ezetimibe to the statin creates a dual-pathway approach that research suggests produces greater LDL reductions than either drug alone.

If plant sterol levels are markedly elevated (several times the upper limit of normal), ask about genetic testing for sitosterolemia. Early identification of this condition changes management significantly and has implications for family members.